Please login to the form below

Not currently logged in
Email:
Password:

LigoCyte

This page shows the latest LigoCyte news and features for those working in and with pharma, biotech and healthcare.

Takeda starts trial of norovirus vaccine

Takeda starts trial of norovirus vaccine

Takeda acquired rights to TAK-214 when it bought US biopharma company LigoCyte in 2012 in a $60m deal and says it remains the only norovirus vaccine candidate in clinical development.

Latest news

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Latest Intelligence

  • Pharma deals during October 2012 Pharma deals during October 2012

    The LigoCyte acquisition is part of the expansion of Takeda's recently formed Vaccine Business Division. ... 64. LigoCyte /Takeda. Acquisition. VLP-based vaccines for GI &respiratory infections (lead product phase I/II).

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GCI Health

GCI Health London is a young, vibrant powerhouse in the European industry with a mission to redefine healthcare communications, starting...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics